Insights into the Impact of Heterogeneous Glycosylation on the Pharmacokinetic Behavior of Follistatin-Fc-Based Biotherapeutics.
Datta-Mannan. Amita A; Huang. Lihua L; Pereira. Jennifer J; Yaden. Benjamin B; Korytko. Andrew A; Croy. Johnny E JE
Key Findings
- FST‑ΔHBS‑Fc produced in CHO cells has variable glycosylation at three sites.
- Higher sialic acid content on the protein reduces clearance in mice and monkeys.
- The asialoglycoprotein receptor 1 (ASGPR‑1) is a key pathway for removing low‑sialic‑acid versions.
- The researchers set target specifications for average sialic acid levels to limit rapid clearance.
Practical Outcomes
- If you ever consider using a follistatin‑315 Fc‑fusion product, look for formulations that report high sialic acid content, as this will likely give a longer half‑life. Products lacking this detail may be cleared quickly and be less effective. However, the study is technical and does not provide direct dosing or usage guidelines for self‑experimentation.
Summary
The study shows that a lab‑made version of follistatin‑315 attached to an antibody fragment (FST‑ΔHBS‑Fc) is covered with different sugar chains, and the amount of a specific sugar called sialic acid determines how quickly the body clears it. More sialic acid means the protein stays in the bloodstream longer, while less leads to faster removal via a liver receptor.
Abstract
Follistatin 315 heparan sulfate-binding deficient mutant human IgG4 Fc fusion (FST-ΔHBS-Fc) is a follistatin (FST) based Fc fusion protein currently being developed as a novel therapy for several potential indications, including muscle wasting. Previous assessments of the pharmacokinetics and therapeutic activity of FST-ΔHBS-Fc have shown a close association of the exposure-response relationship. The current work builds upon these initial studies by investigating the glycosylation characteristics of FST-ΔHBS-Fc after recombinant expression and its impact on the pharmacokinetics in mice and Cynomolgus monkeys. The data presented indicate that FST-ΔHBS-Fc is heterogeneously glycosylated at the three putative sites in FST when recombinantly expressed in stably transfected Chinese hamster ovary cells. Such carbohydrate heterogeneity, especially with regards to sialic acid incorporation, directly results in sugar-dependent clearance in both mice and Cynomolgus monkeys. Examination of the pharmacokinetics of FST-ΔHBS-Fc molecules containing variable sialic acid content in asialoglycoprotein receptor 1 (ASPGR-1) knockout mice supports the receptor's role as part of the clearance mechanism of the molecules. Based on the evaluation of several variably sialylated lots of material in pharmacokinetic assessments, we define specifications for average sialic acid incorporation into FST-ΔHBS-Fc that result in limited sugar-mediated clearance. Taken together, these studies highlight the importance of establishing an early understanding of the glycosylation/pharmacokinetic relationships of FST-ΔHBS-Fc, which will provide a basis for future application toward optimal systemic drug delivery and dosing strategies.
Study Information
pubmed
2015
2015-09-09T00:00:00.000Z
10.1124/dmd.115.064519
9
47